Simple, phage-based (FASTPlaque) technology to determine rifampicin resistance of Mycobacterium tuberculosis directly from sputum

International Journal of Tuberculosis and Lung Disease

Volumn 8, Issue 9, 2004, Pages 1114-1119

  Albert, Heidi ^a   Trollip, A ^a   Seaman, T ^a   Mole, R J ^b  

^a NATIONAL HEALTH LABORATORY SERVICE   (South Africa)

^b Biotec Laboratories Ltd   (United Kingdom)

Author keywords

FASTPlaque; Multidrug resistant tuberculosis; Phage amplification; Rifampicin resistance; Susceptibility testing

Indexed keywords

ISONIAZID; RIFAMPICIN; STREPTOMYCIN;

ADULT; ARTICLE; BACTERIOPHAGE; BACTERIUM CULTURE; DEVICE; DIAGNOSTIC ACCURACY; DISEASE TRANSMISSION; FEMALE; HUMAN; HUMAN CELL; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; MULTIDRUG RESISTANCE; MYCOBACTERIUM TUBERCULOSIS; PHAGE DISPLAY; PRIORITY JOURNAL; PROGNOSIS; SMEAR; SPUTUM ANALYSIS; TECHNOLOGY; TUBERCULOSIS;

ANTIBIOTICS, ANTITUBERCULAR; AUTOMATION; BACTERIOLOGICAL TECHNIQUES; BACTERIOPHAGE TYPING; DNA, BACTERIAL; DRUG RESISTANCE, MICROBIAL; DRUG RESISTANCE, MULTIPLE; HUMANS; MICROBIAL SENSITIVITY TESTS; MYCOBACTERIUM TUBERCULOSIS; REPRODUCIBILITY OF RESULTS; RIFAMPIN; SENSITIVITY AND SPECIFICITY; SPUTUM;

EID: 4444258647     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Stop TB Working Group for DOTS-Plus for MDR-TB. A prioritised research agenda for DOTS-Plus for multidrug-resistant tuberculosis (MDR-TB). Int J Tuberc Lung Dis 2003; 7: 410-414.
2. Espinal M A, Kim S J, Suarez P G, et al. Standard short-course chemotherapy for drug-resistant tuberculosis: treatment outcomes in 6 countries. JAMA 2000; 283: 2537-2545.
3. World Health Organization. Anti-tuberculosis drug resistance in the world. The WHO/IUATLD Global Project on Anti-tuberculosis Surveillance. WHO/TB/97.229. Geneva, Switzerland: WHO, 1997.
4. Becerra M C, Bayona J, Freeman J, Farmer P E, Kim J Y. Redefining MDR-TB transmission 'hot spots'. Int J Tuberc Lung Dis 2000; 4: 387-394.
5. Mitchison D A, Nunn A J. Influence of initial drug resistance on the response to short course chemotherapy of pulmonary tuberculosis. Am Rev Respir Dis 1986; 133: 423-430.
6. Goble M, Iseman M D, Madsen L A, et al. Treatment of 171 patients with pulmonary tuberculosis resistant to isoniazid and rifampicin. New Engl J Med 1993; 328: 527-532.
7. Jain N K, Chopra K K, Prasad G. Initial and acquired isoniazid and rifampicin resistance to M. tuberculosis and its implications for treatment. Indian J Tuberc 1992; 39: 121-124.
8. Snider D E, Kelly G D, Cauther G M, et al. Infection and disease among contacts of tuberculosis cases with drug resistant and drug susceptible bacilli. Am Rev Respir Dis 1985; 132: 125-132.
9. Teixeira L, Perkins M D, Johnson J L, et al. Infection and disease among household contacts of patients with multidrug-resistant tuberculosis. Int J Tuberc Lung Dis 2001; 5: 321-328.
10. Kent P T, Kubica G P. Public Health Mycobacteriology. A Guide for the Level III Laboratory. Atlanta, GA: Centres for Disease Control, 1985.
11. Kent J H. The epidemiology of multidrug-resistant tuberculosis in the United States. Atlanta, GA: Division of Tuberculosis Elimination, National Center for Prevention Services, Centers for Disease Control and Prevention, 1993; 77: 1391-1409.
12. Rees C E D, Rostas-Mulligan K, Park S F, Denyer S P, Stewart G S A B, Jassim S A A. Methods for rapid microbial detection. PCT Patent WO92/02633; 1992.
13. Wilson S M. Method to detect bacteria. PCT Patent WO97/ 022713; 1997.
14. Albert H, Heydenrych A, Brookes R, et al. Performance of a rapid phage-based test, FASTPlaqueTB, to diagnose pulmonary tuberculosis from sputum specimens in South Africa. Int J Tuberc Lung Dis 2002; 6: 529-537.
15. Seaman T, Trollip A, Mole R, Albert H. The use of a novel phage-based technology as a practical tool for the diagnosis of tuberculosis in Africa. Afr J Biotech 2003; 2: 40-45.
16. Muzaffar R, Batool S, Aziz F, Naqvi A, Rizvi A. Evaluation of the FASTPlaqueTB assay for direct detection of Mycobacterium tuberculosis in sputum specimens. Int J Tuberc Lung Dis 2002; 6: 635-640.
17. Marei A M, El-Behedy E M, Mohtady H A, Afify A F. Evaluation of a rapid bacteriophage-based method for the detection of Mycobacterium tuberculosis in clinical samples. J Med Microbiol 2003; 52: 331-335.
18. Shenai S, Rodrigues C, Mehta A P. Evaluation of a new phage amplification technology for rapid diagnosis of tuberculosis. Indian J Med Microbiol 2002; 20: 194-199.
19. Albert H, Heydenrych A, Mole R, Trollip A P, Blumberg L. Evaluation of FASTPlaqueTB-RIF, a rapid, manual test for the determination of rifampicin resistance from M. tuberculosis cultures. Int J Tuberc Lung Dis 2001; 5: 906-911.
20. Albert H, Trollip A P, Mole R J, Hatch S J B, Blumberg L. Rapid indication of multidrug-resistant tuberculosis from liquid cultures using FASTPlaqueTB-RIF, a manual phage-based test. Int J Tuberc Lung Dis 2002; 6: 523-528.
21. Krishnamurthy A, Rodrigues C, Mehta A P. Rapid detection of rifampicin resistance in M. tuberculosis by phage assay. Indian J Med Microbiol 2002; 20: 211-214.
22. Kisa P, Albay A, Bedir O, Baylan O, Doganci L. Evaluation of FASTPlaqueTB-RIF for determination of rifampicin resistance in Mycobacterium tuberculosis complex isolates. Int J Tuberc Lung Dis 2003; 7: 284-288.
23. Master R N. Mycobacteriology. In: Isenburg H D, ed. Clinical Microbiology Procedures Handbook. Section 3. Volume 1. Washington, DC: American Society for Microbiology, 1992.
24. Enarson D A, Rieder H L, Arnadottir T, Trebucq A. Management of tuberculosis. A guide for low income countries. Paris, France: International Union Against Tuberculosis and Lung Disease, 2000.
25. Allen B W. Tuberculosis bacteriology in developing countries. Med Lab Sci 1984; 41: 400-409.
26. Biotec Laboratories Ltd. FASTPlaqueTB-MDRi product insert. Version 15/09/01. Biotec Laboratories Ltd, Ipswich, UK, 2001.
27. Victor T C, Jordaan A M, van Rie A, et al. Detection of mutations in drug resistance genes of Mycobacterium tuberculosis by a dot-blot hybridisation strategy. Tubercle Lung Dis 1999; 79: 343-348.
28. Landis J R, Koch G G. The measurement of observer agreement for categorical data. Biometrics 1977; 33: 159-174.
29. Dye C, Williams B G. Criteria for the control of drug-resistant tuberculosis. Proc Nat Acad Sci 2000; 97: 8180-8185.
30. World Health Organization. DOTS-Plus: preliminary results and emerging issues. Proceedings of the Meeting of the Stop TB Working Group on DOTS-Plus for MDR-TB. Tallinn, Estonia. 10-12 April 2002. WHO/CDS/TFB/2002.307. Geneva, Switzerland: WHO, 2002.
31. World Health Organization. Guidelines for establishing DOTS-Plus pilot projects for the management of multidrug-resistant tuberculosis (MDR-TB). Gupta R, Arnadottir T, eds. WHO/ CDS/TB/2000.279. Geneva, Switzerland: WHO, 2000.
32. Riska P F, Jacobs W R Jr, Alland D. Molecular determinants of drug resistance in tuberculosis. Int J Tuberc Lung Dis 2000; 4: S4-S10.
33. Taniguchi H, Aramaki H, Nikaido Y, et al. Rifampicin resistance and mutation of the rpoB gene in Mycobacterium tuberculosis. FEMS Microbiol Lett 1996; 144: 103-108.
34. Heifets L B, Cangelosi G A. Drug susceptibility testing of Mycobacterium tuberculosis: a neglected problem at the turn of the centur. Int J Tuberc Lung Dis 1999; 3: 564-581.
35. Libonati J P, Stager C E, Davis J R, Siddiqi S H. Direct antimicrobial drug susceptibility testing of Mycobacterium tuberculosis by the radiometric method. Diagn Microbiol Infect Dis 1988; 10: 41-48.